Pan-cancer landscape of homologous recombination deficiency

Homologous recombination deficiency (HRD) results in impaired double strand break repair and is a frequent driver of tumorigenesis. Here, we developed a genome-wide mutational scar-based pan-cancer Classifier of HOmologous Recombination Deficiency (CHORD) that can discriminate BRCA1- and BRCA2-subtypes. Analysis of a metastatic (n=3,504) and primary (n=1,854) pan-cancer cohort revealed HRD was most frequent in ovarian and breast cancer, followed by pancreatic and prostate cancer. Biallelic inactivation of BRCA1, BRCA2, RAD51C or PALB2 was the most common genetic cause of HRD, with RAD51C and PALB2 inactivation resulting in BRCA2-type HRD. While the specific genetic cause of HRD was cancer type specific, biallelic inactivation was predominantly associated with loss-of-heterozygosity (LOH), with increased contribution of deep deletions in prostate cancer. Our results demonstrate the value of pan-cancer genomics-based HRD testing and its potential diagnostic value for patient stratification towards treatment with e.g. poly ADP-ribose polymerase inhibitors (PARPi).

[1]  Andrea Degasperi,et al.  Author Correction: A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies , 2020, Nature Cancer.

[2]  Jin‐Wook Shin,et al.  Thin-film transistor-driven vertically stacked full-color organic light-emitting diodes for high-resolution active-matrix displays , 2020, Nature Communications.

[3]  M. Dowsett,et al.  Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer , 2020, Nature Communications.

[4]  The Icgctcga Pan-Cancer Analysis of Whole Genomes Consortium.  Pan-cancer analysis of whole genomes , 2020 .

[5]  S. Morganella,et al.  A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies , 2020, Nature Cancer.

[6]  P. Carmeliet,et al.  PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase , 2020, Nature Communications.

[7]  P. Campbell,et al.  Genome Sequencing during a Patient's Journey through Cancer. , 2019, The New England journal of medicine.

[8]  Z. Szallasi,et al.  Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents , 2019, Genome Biology.

[9]  Jose Espejo Valle-Inclan,et al.  GRIDSS, PURPLE, LINX: Unscrambling the tumor genome via integrated analysis of structural variation and copy number , 2019, bioRxiv.

[10]  Liliane Schoofs,et al.  A GABAergic and peptidergic sleep neuron as a locomotion stop neuron with compartmentalized Ca2+ dynamics , 2019, Nature Communications.

[11]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[12]  Romina Royo,et al.  A practical guide for mutational signature analysis in hematological malignancies , 2019, Nature Communications.

[13]  J. Pearson,et al.  Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. , 2019 .

[14]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[15]  A. Gonzalez-Perez,et al.  The mutational footprints of cancer therapies , 2019, bioRxiv.

[16]  E. Cuppen,et al.  5-Fluorouracil treatment induces characteristic T>G mutations in human cancer , 2019, Nature Communications.

[17]  Z. Szallasi,et al.  Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancer , 2019, bioRxiv.

[18]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[19]  R. Pilarski.  The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[20]  E. Cuppen,et al.  Portrait of a cancer: mutational signature analyses for cancer diagnostics , 2019, BMC Cancer.

[21]  Isidro Cortés-Ciriano,et al.  Detecting the mutational signature of homologous recombination deficiency in clinical samples , 2019, Nature Genetics.

[22]  J. Valle,et al.  Biliary tract cancers: current knowledge, clinical candidates and future challenges , 2019, Cancer management and research.

[23]  P. Sachs,et al.  SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells , 2019, Nature Communications.

[24]  M. Stratton,et al.  Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.

[25]  S. Morganella,et al.  A Compendium of Mutational Signatures of Environmental Agents , 2019, Cell.

[26]  Ryan L. Collins,et al.  Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes , 2019, bioRxiv.

[27]  M. Kunitski,et al.  Double-slit photoelectron interference in strong-field ionization of the neon dimer , 2018, Nature Communications.

[28]  J. Reid,et al.  Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer , 2018, British Journal of Cancer.

[29]  S. Sleijfer,et al.  Pan-cancer whole genome analyses of metastatic solid tumors , 2018, bioRxiv.

[30]  A. Jeyasekharan,et al.  Biomarkers for Homologous Recombination Deficiency in Cancer , 2018, Journal of the National Cancer Institute.

[31]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[32]  C. Barbieri,et al.  Molecular Subtypes of Prostate Cancer , 2018, Current Oncology Reports.

[33]  Edison T. Liu,et al.  Mechanism of tandem duplication formation in BRCA1 mutant cells , 2017, Nature.

[34]  P. Sung,et al.  BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing , 2017, Nature.

[35]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[36]  James X. Sun,et al.  Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2017, Cancer discovery.

[37]  C. Isaacs,et al.  Prevalence of homologous recombination deficiency among all tumor types. , 2017 .

[38]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[39]  Christophe Badie,et al.  Mutational signatures of ionizing radiation in second malignancies , 2016, Nature Communications.

[40]  F. Nielsen,et al.  Hereditary breast and ovarian cancer: new genes in confined pathways , 2016, Nature Reviews Cancer.

[41]  A. Bhatt,et al.  Stabilizing lithium metal using ionic liquids for long-lived batteries , 2016, Nature Communications.

[42]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[43]  Hong-Wei Xue,et al.  Arabidopsis PROTEASOME REGULATOR1 is required for auxin-mediated suppression of proteasome activity and regulates auxin signalling , 2016, Nature Communications.

[44]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[45]  L. Symington,et al.  Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? , 2015, Trends in biochemical sciences.

[46]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[47]  Stephen J. Elledge,et al.  Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair , 2015, Nature.

[48]  Jun Yao,et al.  The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression. , 2014, Cell reports.

[49]  Linda Z. Shi,et al.  Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells , 2013, Proceedings of the National Academy of Sciences.

[50]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[51]  S. Powell,et al.  Rad51 Paralog Complexes BCDX2 and CX3 Act at Different Stages in the BRCA1-BRCA2-Dependent Homologous Recombination Pathway , 2012, Molecular and Cellular Biology.

[52]  Jing Hu,et al.  SIFT web server: predicting effects of amino acid substitutions on proteins , 2012, Nucleic Acids Res..

[53]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[54]  S. Cantor,et al.  Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. , 2011, Future oncology.

[55]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[56]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[57]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[58]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[59]  Junjie Chen,et al.  DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains , 2004, Molecular and Cellular Biology.

[60]  R. Moses,et al.  BRCA1 interacts directly with the Fanconi anemia protein FANCA. , 2002, Human molecular genetics.